IR-Center Handelsblatt

Sangui BioTech International Inc.

News Detail

DGAP-News News vom 26.05.2020

Sangui BioTech International Inc.: United States Patent Office grants patent 'Compositions for improved tissue oxygenation by peritoneal ventilation'

DGAP-News: Sangui BioTech International Inc. / Key word(s): Patent
26.05.2020 / 08:32
The issuer is solely responsible for the content of this announcement.

Sangui BioTech:
United States Patent Office grants patent "Compositions

for improved tissue oxygenation by peritoneal ventilation"

Hamburg, May 26, 2020: Effective May 12, 2020, the US Patent Office granted a patent for the technology developed by Sangui (SBT 102) to improve tissue oxygenation through peritoneal ventilation. With this grant, the United States Patent Office follows the European Patent Office, which granted patent protection for this technology in March 2019. A possible application of this technology is the treatment of patients with septic shock. Both patents follows up on animal studies carried out by the ECCPS (Excellence Cluster Cardio-Pulmonary System*), Giessen, Germany.

The studies conducted by the ECCPS have resulted in proof-of concept data, utilizing a related technology to Sangui's unique hemoglobin oxygen carrier technology which is already successfully employed by Granulox, a medical device for treatment of chronic wounds. Granulox is distributed by Sastomed GmbH, a fully owned subsidiary of Mölnlycke Health Care GmbH.

* The ECCPS ( is a joint centre of the Justus-Liebig-University Giessen, the Goethe University Frankfurt and the Max-Planck-Institute for Heart and Lung Research in Bad Nauheim in the field of heart and lung research.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (40) 46093120

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

26.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this